Kellia N. Hicks

FDA investigator

Appears on 28 documents from 2017 to 2025, mostly at sites in India. Most often cites production record review (21 CFR 211.192).

28
Documents on file
5.2
Observations per 483
2017
First seen
2025
Most recent

What they cite most

From 146 observations

Activity by year

2017: 3, 2018: 5, 2019: 2, 2021: 2, 2022: 3, 2023: 7, 2024: 3, 2025: 3

Where

India 23 · Missouri 2 · Nebraska 1 · South Carolina 1

Is Kellia N. Hicks coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

28 documents, newest first
FirmOpen
483 Nephron SC Inc.Aug 22, 2025 · West Columbia, South Carolina
483 Blossom PharmaceuticalsApr 11, 2025
483 Emcure Pharmaceuticals LimitedFeb 25, 2025 · Pune, India
483 CIPLA LIMITEDNov 13, 2024 · Bengaluru, India
483 Alchem International Private LtdJul 22, 2024 · Alwar, India
483 Unexo Life Sciences Private Ltd.May 14, 2024 · New Delhi, India
483 ABRYL LABORATORIES PRIVATE LIMITEDNov 20, 2023 · SAS NAGAR, India

About this profile

What does Kellia N. Hicks inspect?

Kellia N. Hicks appears on 28 documents on file covering 26 sites, mostly in India.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.22 and 21 CFR 211.42.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Kellia N. Hicks is dated Aug 22, 2025.